 Murine monoclonal antibody therapy patient plasma cell leukemia patient primary plasma cell leukemia resistant chemotherapy months daily intravenous injections monoclonal antibodies MoAbs patient clinical status treatment major side effects Serial monitoring blockage myeloma cell proliferation bone marrow myeloma cells S-phase vivo reduction serum calcium serum monoclonal IgG serum C-reactive protein levels serum calcium serum monoclonal IgG C-reactive protein undetectable levels treatment major side effects platelet neutrophil counts therapy transient immunization days initiation treatment recovery myeloma cell proliferation months treatment myeloma cells phase conclusion first clinical trial feasibility MoAbs transient tumor cytostasis reduction toxicities major biologic activities vivo basis development therapy myeloma diseases